Attendees will hear detailed insights and industry best practices from preeminent sector experts and will take away a deeper understanding of and appreciation for manufacturing and various industrialization hurdles unique to bringing durable, potentially curative therapies to patients in need.

The speakers will discuss pressing issues such as how sponsors move from a smaller process to a larger one; whether to approach manufacturing by building in-house, outsourced or hybrid capabilities; key logistical challenges; as well as a deeper dive into specific manufacturing issues facing autologous cell therapies.